Utility of Low Concentrations of Serum Thyroglobulin in Predicting Residual or Recurrent Disease in Patients Treated for Well-Differentiated Thyroid Cancer.

2010 ◽  
pp. P1-568-P1-568
Author(s):  
K Iyengar ◽  
ME Shomali ◽  
KD Burman
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Recurrent Disease ◽  
Serum Thyroglobulin ◽  
Low Concentrations ◽  
Well Differentiated

Serum Thyroglobulin Improves the Sensitivity of the McGill Thyroid Nodule Score for Well-Differentiated Thyroid Cancer

Thyroid ◽  
2014 ◽  
Vol 24 (5) ◽  
pp. 852-857 ◽  
Author(s):  
Patrick Scheffler ◽  
Veronique I. Forest ◽  
Rebecca Leboeuf ◽  
Anca V. Florea ◽  
Michael Tamilia ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodule ◽  
Differentiated Thyroid Cancer ◽  
Serum Thyroglobulin ◽  
Well Differentiated

scholarly journals The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation

2008 ◽  
Vol 158 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Ha T T Phan ◽  
Pieter L Jager ◽  
Jacqueline E van der Wal ◽  
Wim J Sluiter ◽  
John T M Plukker ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Recurrent Disease ◽  
Disease Free Survival ◽  
Serum Thyroglobulin ◽  
Primary Tumors ◽  
Histological Features ◽  
Number Of Patients ◽  
Age Range

ObjectiveThis retrospective study describes the role of serum thyroglobulin (Tg) in relation to tumor characteristics in the prediction of persistent/recurrent disease in patients with differentiated thyroid cancer (DTC) with negative Tg at the time of ablation.DesignBetween 1989 and 2006, 94 out of 346 (27%) patients with DTC had undetectable Tg at the time of 131I ablation and were included in this evaluation. The group of 94 patients consisted of 15 males and 79 females in the age range of 16–89 years with a median follow-up of 8 years (range 1–17). All medical records and follow-up parameters of the 94 patients were evaluated for the occurrence of persistent/recurrent disease. In patients with persistent/recurrent disease hematoxylin-eosin-stained slides of the primary tumors and/or metastatic lesions were also reviewed for histological features including immunostains for Tg.ResultsDuring follow-up, 8 out of 94 (8.5%) patients showed persistent/recurrent disease: in the course of the disease two patients showed Tg positivity, three showed Tg antibody (TgAb) positivity, and the other three showed persistently undetectable Tg and TgAb. Patients who developed Tg and/or TgAb positivity during follow-up had a significantly shorter disease-free survival period when compared with patients with persistently undetectable Tg and TgAb (P<0.006). Histological features were not able to predict the recurrent status.ConclusionsFollow-up of Tg and TgAb in patients with initially negative Tg and TgAb is useful since a number of patients had shown detectable Tg or TgAb during follow-up indicative for persistent/recurrent disease. Tg and TgAb negativity at the time of ablation is not a predictive determinant for future recurrent status.

Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients

1985 ◽  
Vol 10-10 (5-6) ◽  
Author(s):  
MariaElisa Girelli ◽  
Benedetto Busnardo ◽  
Renato Amerio ◽  
Giorgio Scotton ◽  
Dario Casara ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Serum Thyroglobulin ◽  
Well Differentiated

scholarly journals Postablation 131I scintigraphy with neck and thorax SPECT–CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer

2011 ◽  
Vol 164 (6) ◽  
pp. 961-969 ◽  
Author(s):  
Renaud Ciappuccini ◽  
Natacha Heutte ◽  
Géraldine Trzepla ◽  
Jean-Pierre Rame ◽  
Dominique Vaur ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Recurrent Disease ◽  
Whole Body ◽  
Emission Computed Tomography ◽  
Early Assessment ◽  
Serum Thyroglobulin ◽  
Increased Risk ◽  
The Impact

ObjectiveNeck and thorax single photon emission computed tomography with computed tomography (SPECT–CT) improves the reliability of postablation 131I whole-body scan (WBS) for differentiated thyroid cancer (DTC). The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation 131I scintigraphy combining WBS and neck and thorax SPECT–CT with that of the previously known predictive factors.MethodsThis is a single referral center prospective study with a median follow-up of 29 months. Postablation 131I WBS and neck and thorax SPECT–CT were performed in 170 consecutive patients treated between 2006 and 2008. Stimulated serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) levels were measured. The impact on disease-free survival of age; gender; postablation 131I scintigraphy; stimulated serum Tg level; T, N, and M status; and macroscopic lymph node involvement was assessed by univariate and multivariate analyses.ResultsPersistent or recurrent disease was observed in 32 (19%) patients. In the whole group of patients, only positive WBS with SPECT–CT was related to an increased risk of persistent or recurrent disease (hazards ratio (HR)=65.21, 95% confidence interval (CI)=26.03–163.39, P<0.0001). In patients without TgAb (n=146), both positive WBS with SPECT–CT (HR=18.86, 95% CI=5.02–70.85, P<0.0001) and serum Tg level ≥58 ng/ml (HR=4.42, 95% CI=1.18–16.53, P=0.0271) were associated with an increased risk.ConclusionIn patients with DTC, the cross analysis of postablation 131I scintigraphy with neck and thorax SPECT–CT and stimulated serum Tg level enables early assessment of the risk of persistent or recurrent disease.

scholarly journals Recurrence of differentiated thyroid cancer in the elderly

2013 ◽  
Vol 168 (4) ◽  
pp. 549-556 ◽  
Author(s):  
Christopher S Hollenbeak ◽  
Melissa M Boltz ◽  
Eric W Schaefer ◽  
Brian D Saunders ◽  
David Goldenberg
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Elderly Patients ◽  
Differentiated Thyroid Cancer ◽  
Recurrent Disease ◽  
Significant Risk ◽  
Cox Proportional Hazards ◽  
Competing Risk ◽  
Well Differentiated ◽  
The Impact

ObjectiveData from the Surveillance Epidemiology and End Results Medicare-linked database were used to estimate the incidence of and risk factors associated with recurrent thyroid cancer, and to assess the impact of recurrence on mortality following diagnosis, controlling for mortality as a competing risk.DesignWe identified 2883 patients over 65 years of age diagnosed with a single, primary well-differentiated thyroid cancer between 1995 and 2007. A recurrence was considered if the patient had evidence of I-131 therapy, imaging for metastatic thyroid carcinoma, or complete thyroidectomy beyond 6 months of diagnosis. Competing risk regressions were performed using Cox proportional hazards models with 1- and 2-year landmarks.ResultsRecurrence was observed in 1117 (39%) of the 2883 patients in the cohort. Age, stage, and treatment status were significant risk factors for developing recurrent disease (P<0.0001). Patients with recurrent disease had a higher risk of all-cause mortality within 10 years of diagnosis than patients with no recurrence at 1- and 2-year landmarks. Patients with follicular histology and a recurrence were less likely to die from cancer (hazard ratio 0.54; P=0.03) than patients with no recurrence.ConclusionsThe rate of recurrence of well-differentiated thyroid carcinomas in this sample of elderly patients was 39%. Extent of disease and older age negatively impacted the risk of recurrence from differentiated thyroid cancer. In these data, patients with follicular histology and a recurrence were less likely to die, suggesting that mortality and recurrence are competing risks. These data should be taken into account with individualized treatment strategies for elderly patients with recurrent malignant thyroid disease.

scholarly journals Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer

2004 ◽  
Vol 150 (5) ◽  
pp. 649-653 ◽  
Author(s):  
H Taylor ◽  
S Hyer ◽  
L Vini ◽  
B Pratt ◽  
G Cook ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Recurrent Disease ◽  
Clinical Findings ◽  
Whole Body ◽  
Serum Thyroglobulin ◽  
Body Scanning ◽  
Extra Information ◽  
Disease Free

OBJECTIVE: To assess the value of the diagnostic whole body (131)I scan after thyroidectomy and (131)I ablation. DESIGN: Retrospective analysis of all patients with differentiated thyroid cancer treated in one centre between 1990 and 2000. RESULTS: A total of 153 consecutive patients who underwent diagnostic scanning following ablative therapy were identified. This diagnostic scan was positive in 20 patients (13%) and faintly positive in 16 patients (11%). The majority (117 patients) had negative scans. Of the 20 patients with positive scans, four received no further treatment, nine showed no abnormal uptake following a second ablative (131)I dose and seven had uptake in the thyroid bed (six) or in neck nodes (one) after repeat ablation. OUTCOME: In the group with positive scans, the four patients who received no further treatment and the nine with a negative second ablation scan remained disease free during follow-up. No patient with a positive diagnostic scan received additional (131)I therapy which would not otherwise have been given based on the clinical findings, serum thyroglobulin (Tg) values or the presence of anti-Tg antibodies. Ten of the patients with negative scans developed recurrent disease which was always detected clinically or by a rising serum Tg value. CONCLUSIONS: Diagnostic whole body (131)I scans add little extra information and in our experience do not influence patient management. They should be reserved for patients in whom serum Tg levels are unreliable because of the presence of antibodies or when there is clinical suspicion of tumour.

Sign in / Sign up

Export Citation Format

Share Document